Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06597721 · ClinicalTrials.gov registry record · Phase 1

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

A Phase 1 study of Advanced Solid Tumor, sponsored by Adcendo ApS.

Recruiting
Registry status
Phase 1
Development phase
210
Enrollment target
10
Study locations

NCT06597721 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Adcendo ApS. The registered enrollment target is 210 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06597721, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Adcendo ApS.

RECRUITING
Registry status
Phase 1
Development phase
210 participants
Enrollment target
10
Study locations

Study Summary

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG ADCE-T02

Study Locations (10)

Texas

  • MD Anderson Cancer Center - Houston
  • START San Antonio - San Antonio

Victoria

  • Peninsula and South Eastern Haematology and Oncology Group (PSEHOG) - Frankston
  • Cabrini Hospital - Malvern

Arkansas

  • Highlands Oncology Group - Rogers

Connecticut

  • Yale University Cancer Center - New Haven

Massachusetts

  • Massachusetts General Hospital - Boston

New South Wales

  • Scientia Clinical Research - Randwick

South Australia

  • Southern Oncology Clinical Research Unit - Bedford Park

Western Australia

  • Linear Clinical Research - Nedlands

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2024-11-25
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Adcendo ApS

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06597721

The ClinicalTrials.gov registry entry for NCT06597721 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Adcendo ApS, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ADCE-T02 is the first listed.

NCT06597721 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Texas, Victoria, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06597721 about?

NCT06597721 is a clinical study titled "ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours". Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M...

What is the current status of trial NCT06597721?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2024-11-25. Estimated completion is 2026-12-31.

What conditions does trial NCT06597721 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06597721?

The interventions under investigation include: ADCE-T02 (DRUG).

Who is sponsoring clinical trial NCT06597721?

This trial is sponsored by Adcendo ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06597721 being conducted?

This trial has 10 study locations across Arkansas, Connecticut, Massachusetts, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.